Meredith M. Regan, ScD, on Early Breast Cancer: Updated Results From the TEXT and SOFT Trials

January 12, 2022 By The ASCO Post Staff

Meredith M. Regan, ScD, of Dana-Farber Cancer Institute, discusses findings that point to the potential benefits of using adjuvant exemestane plus ovarian function suppression (OFS) to treat premenopausal women with hormone receptor–positive early breast cancer. This conclusion came after 13 years of median follow-up on the TEXT and SOFT trials, during which this regimen was compared with tamoxifen and OFS (Abstract GS2-05).

Related Content